



bismuth subcitrate potassium/ metronidazole/ tetracycline hydrochloride hard capsules (Pylera®)

Flynn Pharma Ltd

04 October 2024

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

bismuth subcitrate potassium/ metronidazole/ tetracycline (Pylera®) is accepted for restricted use within NHSScotland.

Indication under review: In combination with omeprazole, for the eradication of *Helicobacter pylori* and prevention of relapse of peptic ulcers in patients with active or a history of *H. pylori* associated ulcers

SMC restriction: restricted to use in accordance with clinical guidelines for the eradication of *H. pylori*

Pylera® is a new combination medicine of existing medicines, with limited net budget impact.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including **11 June 2024**.

Chair
Scottish Medicines Consortium